

# 26 June 2026, Friday



## 58<sup>th</sup> EPC/IAP joint meeting



Acibadem University Istanbul | TURKIYE  
JUNE 24<sup>th</sup>-27<sup>th</sup> | 2026

26 June 2026, Friday												
	BOSPHORUS HALL	TOPKAPI HALL	GALATA HALL	TAKSİM HALL	KADIKÖY HALL	A3 ROOM	BEBEK POSTER HALL	MODA POSTER HALL	BESİKTAŞ POSTER HALL			
07:00-07:30	EPC/IAP RUN Against Pancreatic Cancer Caddebostan Coast, 07:00-08:30						EPC Public Affairs Committee				07:00-07:30	
07:30-08:30											07:30-08:30	
08:30-09:45	Translational Breakthroughs in Pancreatology & EPC - Lifetime Achievement Award Lecture & Palade Prize Lecture	Why Pediatric to Adult Integration Matters in Pancreatic Diseases										08:30-09:45
09:45-10:15	Satellite Symposium	COFFEE BREAK & SPONSORS EXHIBITION				EPC & JPS				09:45-10:15		
10:15-10:45	Live Advanced-EUS & Extended EUS Procedures	Best Abstracts Cystic Tumors & PanNET	The Fatty Pancreas International Consensus Report: Lessons Learned and Roadmap for the Future		TRANSPAN					10:45-13:00		
10:45-13:00	LUNCH BREAK & POSTER ROUNDS & SPONSORS EXHIBITION											
13:00-14:00	Early Detection & Treatment of Pancreatic Cancer	Best Abstracts Pancreatitis & Endoscopy	Best Abstracts Varia-II		PANDORA Consortium					14:00-15:45		
14:00-15:45	Satellite Symposium	IAP - General Assembly	COFFEE BREAK & SPONSORS EXHIBITION									15:45-16:15
15:45-16:15	Rudolf Ammann & Best Abstracts Awardee Session										16:15-17:00	
16:15-17:00	EPC - General Assembly										17:00-18:30	

BOSPHORUS HALL		
08:30-08:50	IAP Palade Prize Lecture	Chairs: Vinciane Rebours, (Paris, France), Min Li (Oklahoma City, USA)
	Acinar Cells: at the Heart of the Pancreas - and Mine	Francisco X. Real (Madrid, Spain)
08.50-09.55	Translational Breakthroughs in Pancreatology	Chairs: Roland Rad (Munich, Germany), Min Li (Oklohoma City, USA), Reiner Heuchel (Stockholm, Sweden)

08.50-09.03	Decoding Pancreatic Cancer Ecosystems with Single-Cell and Spatial Omics	William L. Hwang (Boston, USA)
09.03-09.16	Genotype-Guided Treatment of Pancreatic Cancer: Exploiting DNA Repair and Stromal Vulnerabilities	Alexander Kleger (Ulm, Germany)
09.16-09.29	Vulnerabilities, and Clinical Translation	Raghu Kalluri (Houston, USA)
09.29-09.42	Decoding Pancreatic Carcinogenesis: Genomic Roadmaps from Precursor Lesions to Invasive Cancer	Laura D. Wood (Baltimore, USA)
09.42-09.55	<b>Best Translational Abstracts</b> Local delivery of CAR T cells using fibrin glue enables cellular immunotherapy for pancreatic ductal adenocarcinoma	Tengis Tschaidse (Munich, Germany)
<b>09.55-10.15</b>	<b>EPC - Lifetime Achievement Awardee Lecture</b>	<b>Chairs: Güralp O. Ceyhan (Istanbul, Türkiye), Gabriele Carpuso (Milan, Italy)</b>
	Why Basic & Translational Research is Dependent on the Clinician's Eye - Even from a Surgeon!	Helmut Friess (Munich, Germany)
<b>10.15-10.45</b>	<b>Coffee Break</b>	<b>Satellite Symposium</b>
<b>10.45-13.00</b>	<b>Live Advanced EUS &amp; Extended EUS Procedures</b>	<b>Chairs: Albrecht Neeße (Göttingen, Germany), Andrew Metz (Melbourne, Australia), Dilek Oğuz, (Ankara, Turkey)</b>
10.45-11.00	Global Perspective & Consensus: Expanding Roles of EUS Interventions within Surgical Care Pathways - Where are the Limits?	Andrew Metz (Melbourne, Australia)
11.00-11.30	Live Endoscopy (Patient 1)	Gürhan Sisman (Istanbul, Türkiye) & Pieter Hindryckx (Gent, Belgium)
11.30-11.45	EUS-Guided Phosphorus-32 Intratumoral Brachytherapy in Locally Advanced PDAC: Redefining Local Control & Downstaging Potential	Stefano F. Crino (Verona, Italy)
11.45-12.15	Live Endoscopy (Patient 2)	Gürhan Sisman (Istanbul, Türkiye) & Pieter Hindryckx (Gent, Belgium)
12.15-12.30	Artificial Intelligence in Pancreatic EUS: Where do We Stand?	Adrian Saftoiu (Craiova, Romania)
12.30-13.00	Live Endoscopy (Patient 3)	Gürhan Sisman (Istanbul, Türkiye) & Pieter Hindryckx (Gent, Belgium)
<b>13.00-14.00</b>	<b>Lunch</b>	
<b>14.00-15.45</b>	<b>Early Detection &amp; Treatment in Pancreatic Cancer</b>	<b>Chair: Shounak Majumder (Rochester, USA), Masayuki Sho (Nara, Japan), Mert Erkan (Istanbul, Türkiye)</b>
14.00-14.14	Liquid Biopsy for Early Detection of Pancreatic Cancer and Its Impact on Treatment Monitoring and Guiding	Shounak Majumder (Rochester, USA)
14.14-14.28	MRI or EUS - What is the Best Modality to Screen for Early Pancreatic Cancer	Stephen Philcox (President of Australian Pancreatic Club) (Newcastle, Australia)
14.28-14.42	Multidisciplinary Approaches and Survival Benefits of Surgery in Locally Advanced Pancreatic Cancer	İhsan Ekin Demir (Munich, Germany)

14.42-14.56	Advanced Preoperative Imaging Techniques in Assessing Tumor Resectability Post-Neoadjuvant Therapy: Is Maging Ready to Help Us?	Rickmer Braren (Hamburg, Germany)
14.56-15.10	Triangle & Advanced Vascular Resection in LAPC - Why It is a Must in LAPC Surgery?	Shailesh Shrikhande (Mumbai, India)
15.10-15.30	When Resection then Minimally Invasive or Open? - what DIPLOMA Showed Us	Marc G. Besselink (Amsterdam, Netherlands)
15.30-15.45	Optimal Dose of Pancreatic Enzyme Replacement Therapy (PERT) for Pancreatic Exocrine Insufficiency (PEI) in Different Pancreatic Diseases: European PEI Registry: Final Results	Juan Enrique Dominguez Munoz (Santiago de Compostela, Spain)
<b>15.45-16.15</b>	<b>Coffee Break</b>	<b>Satellite Symposium</b>
<b>16.15-17.00</b>	<b>Rudolf Ammann &amp; Best Abstracts Awardee Session</b>	<b>Chairs: Güralp O. Ceyhan (Istanbul, Türkiye), Gabriele Capurso (Milan, Italy), Vinciane Rebours (Paris, France), Pramod Garg (New Delhi, India)</b>
16.15-16.32	<b>Rudolf Amman Award/ Nordmark</b> <i>Heavy metals in cigarette smoke strongly inhibit pancreatic ductal function and promote development of chronic pancreatitis</i>	Petra Pallagi (Szeged, Hungary)
16.32-16.39	<b>Best Abstract Clinical Science/EPC</b> <i>Normal Saline or Lactated Ringer's Solution in Acute Pancreatitis Resuscitation: a multicenter randomized clinical trial (WATERLAND)</i>	Lucia Guilabert (Elche, Spain)
16.39-16.46	<b>Best Abstract Clinical Science/IAP</b> <i>Spatial Transcriptomics Reveals Molecular Trajectories and Immune Landscapes in IPMN and IPMN-derived Pancreatic Cancer</i>	Ming Cui (Beijing, China)
16.46-16.53	<b>Best Abstract Basic Science/EPC</b> <i>Hepatic Innervation as a Regulator of the Pre-Metastatic Niche and Liver Metastasis in Pancreatic Cancer</i>	Eyüp Yöndem (Munich, Germany)
16.53-17.00	<b>Best Abstract Basic Science/IAP</b> <i>A stem cell-engineered immune-competent PDAC organoid reveals CAF-lineage specific therapeutic vulnerabilities</i>	Yujie Li (Sydney, Australia)
17.00-18.30	EPC - General Assembly	
<b>TOPKAPI HALL</b>		
<b>08.30-09:50</b>	<b>Why Pediatric to Adult Integration Matters in Pancreatic Diseases</b>	<b>Chairs: Sanjay Pandanaboyana (New Castle, UK), Maisam Abu-El-Hajja (Cincinnati, USA)</b>
08.30-08.45	CFTR-Associated and Other Pediatric Pancreas Diseases as a Bridge to Adult Care	József Maléth (Szeged, Hungary)
08.45-09.00	Genetic Architecture of Pancreatitis: From Childhood Presentation to Adult Chronic Disease	Andrea Geisz-Fremy (Boston, USA)
09.00-09.15	Classification and Imaging of Pediatric Pancreatitis - Implications for Adult Practice	Temel Tirkes (Indianapolis, USA)
09.15-09.30	What Pediatric Cohorts Teach Us About Lifelong Pancreatic Disease	Maisam Abu-El-Hajja (Cincinnati, USA)
09.30-09:45	Surgery of the Pediatric Pancreas, When It Can't Wait till to Adolescence and What Type of Surgery then?	Sanjay Pandanaboyana (Newcastle, UK)
<b>10.15-10.45</b>	<b>Coffee Break</b>	
<b>10.45-13.00</b>	<b>Best Abstracts Cystic Tumors &amp; PanNET</b>	<b>Chairs: Müjde Soytürk (Izmir, Türkiye)</b>

10:45-10:54	<i>Recurrence After Resection of Non-Invasive Intraductal Papillary Mucinous Neoplasms: A Multicenter Analysis of Risk Factors and Clinical Impact</i>	Riccardo Pellegrini (Padova ,Italy)
10:54-11:03	<i>Optimizing pancreatic cyst surveillance: a cost-effectiveness analysis using microsimulation modelling</i>	Oliver White (Rotterdam ,The Netherlands)
11:03-11:12	<i>Exposome and cyst features are associated with distinct histotypes and malignancy risk in surgically resected IPMNs: preliminary results from the multicenter ESPRESSO MACCHIATO study</i>	Gabriele Capurso (Milan ,Italy)
11:12-11:21	<i>Decoding IPMN Heterogeneity: Matched Molecular Profiling from Cyst Wall, Fluid and Plasma in the GERPACYST Registry</i>	Matthäus Felsenstein (Berlin ,Germany)
11:21-11:30	<i>Real-world EUS evaluation of pancreatic cystic lesions: cytology-based classification and predictors of mucinous cysts and high grade dysplasia</i>	Charalampos Thanos (Athens ,Greece)
11:30-11:39	<i>Clinical, demographic and EUS features of pancreatic cysts: a nationwide multicenter study of the Pancreas Working Group</i>	
11:39-11:48	<i>Reappraisal of the concept of “timely surgery” according to follow-up vs upfront surgery strategy for IPMNs</i>	Riccardo Pellegrini (Padova ,Italy)
11:48-11:57	<i>AI-based radiomics for pancreatic cysts: high diagnostic performance amid persistent translational gap</i>	Johannes D. Lettner (Freiburg ,Germany)
11:57-12:06	<i>Complementary ex vivo models reveal determinants of targeted therapy response in nonfunctioning pancreatic neuroendocrine tumors</i>	Anna Battistella (Milano ,Italy)
12:06-12:15	<i>More Parenchyma, Less Safety? Two Decades of Pancreatic Neuroendocrine Tumor Surgery</i>	Carola Focke (Freiburg ,Germany)
12:15-12:24	<i>IRE-centered multidisciplinary treatment for unresectable pancreatic acinar-MiNEN: durable 5-year survival in an ultra-rare pancreatic malignancy</i>	Yingjie Wang (Zhengzhou ,China)
12:24-12:33	<i>Multi-omics profiling of CUX1 transcription factor revealed epigenetic regulation in PanNETs: Unlocking new therapeutic targets through targeting the CUX1-HAT1/EZH2 pathway</i>	Maryam Khosravian (Heidelberg ,Germany)
12:33-12:42	<i>Endoscopic Photodynamic Therapy Under Direct Visualization via Pancreatoscopy: An Innovative treatment for Pancreatic MD-IPMN</i>	Wei Liu (Changsha City ,China)
12:42-12:51	<i>Evaluation of the treatment strategy for small non-functioning pancreatic neuroendocrine neoplasms: resection versus observation</i>	Wataru Izumo (Yamanashi ,Japan)
12:51-13:00	<i>Primary Tumor Resection Prior to Peptide Radionuclide Receptor Therapy Improves Survival in Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-analysis</i>	Sándor Orbán (Budapest ,Hungary)
<b>13.00-14.00</b>	<b>Lunch</b>	
<b>14.00-15.45</b>	<b>Best Abstracts Pancreatitis &amp; Endoscopy</b>	<b>Chairs: Santhi Vege (Rochester, USA), Livia Archibugi (Milan, Italy)</b>
14.00-14.09	<i>Pain in Chronic Pancreatitis: Multidimensional associations with neuropsychological factors, neurometabolic alterations, and corticolimbic connectivity</i>	Abdul Rasheed Mohammed (Hyderabad ,India)

14.09-14.18	<i>Trajectories of pain processing in recurrent acute and chronic pancreatitis: a longitudinal quantitative sensory testing study</i>	<i>Louise Kuhlmann (Aalborg ,Denmark)</i>
14.18-14.27	<i>Risk of pancreatic disease in families with metabolic dysfunction-associated steatotic liver disease: a population-based multigenerational cohort study</i>	<i>Miroslav Vujasinovic (Stockholm ,Sweden)</i>
14.27-14.36	<i>Long term evolution of type 2 autoimmune pancreatitis, evidence from a large french cohort</i>	<i>Clémence Descourvières (Clichy ,France)</i>
14.36-14.45	<i>Clinical Practice of Modified Pancreatic Duct Stone Classification (Xi-Panc) in the Treatment of Chronic Pancreatitis</i>	<i>Xue Yang (Xi'an ,China)</i>
14.45-14.54	<i>Managed risk of abdominal compartment syndrome in patients with acute severe pancreatitis</i>	<i>Ivanna A. Shchyhel (Kyiv ,Ukraine)</i>
14.54-15.03	<i>Combination of non-steroidal anti-inflammatory drugs plus pancreatic duct stent placement after unintentional pancreatic duct cannulation is superior to NSAIDs alone in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis</i>	<i>Mike J.P. de Jong (Nijmegen ,The Netherlands)</i>
15.03-15.12	<i>Machine Learning versus QNI Score for Predicting Step-Up Therapy After Initial EUS-Guided Drainage of Pancreatic Fluid Collections</i>	<i>Marcel Razpotnik (Berlin ,Germany)</i>
15.12-15.21	<i>International Delphi Consensus on Training in Diagnostic and Therapeutic Endoscopic Ultrasound</i>	<i>Matteo Tacelli (Milano ,Italy)</i>
15.21-15.30	<i>Closing the ERCP quality gap: an open digital platform for real-time competency and outcome tracking</i>	<i>Lukas Erhart (St. Pölten ,Austria)</i>
15.30-15.39	<i>Redefining vascular patterns in focal lesions with EUS Detective Flow Imaging: a multicenter interobserver agreement study</i>	<i>Riccardo Di Pangrazio (Roma ,Italy)</i>
<b>15.45-16.15</b>	<b>IAP - General Assembly</b>	
<b>GALATA HALL</b>		
<b>10.45-13.00</b>	<b>International Multidisciplinary Consensus Report on Fatty Pancreas: Lessons Learned and Roadmap for the Future</b>	<b>Chairs: Vinciane Rebours (Paris, France), J. -Matthias Löhrl (Heidelberg, Germany)</b>
10.45-10.50	Welcome & Opening Remarks	Vinciane Rebours (Paris, France), J. -Matthias Löhrl (Stockholm, Sweden)
10.50-11.00	Fatty Pancreas: Background, Consensus Methodology, and Key Concepts	Miroslav Vujasinovic (Stockholm, Sweden)
11.00-11.10	Histopathological Features of Fatty Pancreas	Aslıhan Yavaş (Dusseldorf, Germany)
11.10-11.25	Imaging Modalities and Radiological Evaluation of Fatty Pancreas	Muşturay Karçaaltıncaba (Ankara, Türkiye)
11.25-11.35	Clinical Implications of Fatty Pancreas in Acute and Chronic Pancreatitis	Pramod Garg (New Delhi, India)
11.35-11.45	Fatty Pancreas in Pancreatic Neoplasms: IPMN and PDAC Perspectives	Giovanni Marchegiani (Padova, Italy)
11.45-11.55	Metabolic Consequences of Fatty Pancreas: $\beta$ -Cell Function and Glucose Regulation	Laszlo Czako (Szeged, Hungary)
11.55-12.05	Surgical Considerations and Management of Fatty Pancreas	Sanjay Pandanaboyana (New Castle, UK)

12.05-12.25	Therapeutic Strategies, Key Conclusions, and Future Directions in Fatty Pancreas Research	İhsan Ekin Demir (Munich, Germany)
12.25-13.00	Panel Discussion: Multidisciplinary Perspectives and Audience Q&	Chairs and All Speakers
<b>13.00-14.00</b>	<b>Lunch</b>	
<b>14.00-15.40</b>	<b>Best Abstracts - Varia II</b>	<b>Chairs: Aydin Seref Köksal (Ankara, Turkiye), Laura Maggino (Verona, Italy)</b>
14.00-14.09	Small intestinal bacterial overgrowth as a possible cause of falsely reduced fecal elastase-1 levels	Natalya Gubergrits (Odesa, Ukraine)
14:09-14:18	A Patient-Reported Tool for All PEI Etiologies? Validation of the PEI-Q and Its Utility in Monitoring Response to PERT	Juan Enrique Dominguez Muñoz (A Coruña, Spain)
14:18-14:27	Association between pancreatic enzyme replacement therapy and mortality in pancreatic cancer: a matched case-control study	Ana Dugic (Heidelberg, Germany)
14:27-14:36	10-year empirical survival rates following upfront pancreatectomy for pancreatic ductal adenocarcinoma. A bi-institutional analysis	Susanna Tondato (Verona, Italy)
14:36-14:45	Pre-Test Probability Drives the Diagnostic Yield of Fecal Elastase-1: A Multicenter Real-World Study	Marta Andreozzi (Milano, Italy)
14:45-14:54	The mouse cancer cell line atlas reveals core principles of tissue-specific cancer evolution	Sebastian Mueller (Munich, Germany)
14:54-15:03	Exocrine pancreatic insufficiency and nutritional status in resectable and borderline resectable periampullary tumors: A prospective longitudinal study	Eric Herrero Fonollosa (Terrassa, Spain)
15:03-15:12	Whole genome sequencing-using long-reads to identify structural variants and methylation signatures in IPMN evolution into malignancy	Riccardo Farinella (Pisa, Italy)
15:12-15:21	Preoperative transhepatic portomesenteric venous stenting in locally advanced pancreatic cancer with venous occlusion and associated varices	Matthias Ilmer (Rochester, USA)
15:21-15:30	SHP2 regulates CAF activity and adaptive stromal remodeling during vertical RAS pathway inhibition in pancreatic cancer	Steffen Johannes Keller (Freiburg Im Breisgau, Germany)
15:30-15:39	Predictors of fecal elastase testing completion in outpatient and inpatient settings: a single center retrospective analysis	Arjun Chatterjee (Cleveland, USA)
<b>KADIKÖY HALL</b>		
<b>10.45-13.00</b>	<b>TRANSPAN</b>	
<b>13:00-14:00</b>	<b>Lunch</b>	
<b>14:00-15.45</b>	<b>PANDoRA Consortium</b>	
<b>15:45-16:15</b>	<b>Coffee Break</b>	
<b>A3 ROOM</b>		
<b>07.30-08.30</b>	<b>EPC Public Affairs Committe</b>	
<b>10.15-10.45</b>	<b>EPC &amp; JPS</b>	

**Bebek Poster Hall / 13.00 - 14.00**

\*Please kindly note that each presentation is allocated 4 minutes (3-minute presentation + 1-minute discussion)

AbsRef	Pub Number	Title	Presenter
<b>Group - 18</b>		<b>Chairs: Bo Kong (Heidelberg, Germany), Özlem Sönmez (Istanbul, Türkiye)</b>	
384	POTH-014	Network-based identification of stage-specific interception points in pancreatic disease progression	Yan Bi
585	PPCC-065	Injecting Innovation: EUS-Guided Phosphorus-32 as a Local Ablative Boost in Pancreatic Cancer Therapy	Rodrigo Montoto Meijide
599	PPCC-066	The role of detective flow imaging- endoscopic ultrasound in the characterization of unexplained biliary strictures: a retrospective study	Leila Babaiyan
606	PPCC-067	Beyond Presence: Patterns of Angioinvasion as Determinants of Aggressiveness in Pancreatic Ductal Adenocarcinoma	Samuele Grandi
632	PPCC-068	Chemotherapy-induced liver injury during Neoadjuvant Treatment in Pancreatic Cancer: A Systematic Review and Meta-analysis Randomized Controlled Trials	Alessio Marchetti
645	PPCC-069	High-grade PanIN/Carcinoma in situ Incidentally Discovered in a Resected Pancreas with IPMN: A Retrospective Radiological Review	Yoshihiro Hamada
651	PPCC-070	Distinct Lipid Signatures in Early-Onset Pancreatic Ductal Adenocarcinoma	Liu Longyu
653	PPCC-071	Diagnostic work-up of patients with suspected pancreatic cancer: A prospective single-centre study	Tamas Hussein
654	PPCC-072	Tumor microbiota profiling identifies microbial signatures associated with clinical and radiological features in locally advanced pancreatic ductal adenocarcinoma	Giacomo Marcozzi
660	PPCC-073	Prognostic impact of positive margin location after R1 pancreatic resections: a survival analysis	Orfeas Varvarelis
663	PPCC-074	Clinical impact of positive drain fluid amylase after pancreatectomy: association with postoperative complications and hospital stay	Vasiliki Alkmini Themelidi
671	PPCC-075	The impact of preoperative biliary drainage on the occurrence of postoperative complications after pancreaticoduodenectomy	Vladyslav Bondar
677	PPCC-076	Giant (18 cm) primary epithelioid gastrointestinal stromal tumor of the pancreatic tail: Case Report and Literature Review	Vyronas Argyris
678	PPCC-077	Analysis of the diagnostic utility of endosonography-guided biopsy in pancreatic solid lesions	Barbara Włodarczyk
687	PPCC-078	Features of pancreatic cancer in the tunisian population	Amal Khsiba
<b>Group - 19</b>		<b>Chairs: Daniel Öhlund (Umea, Sweden), Bahadır Bozkırlı (Istanbul, Türkiye)</b>	
784	POTH-024	Fatty changes in resected pancreatic neck	Mariia Kiriukova
689	PPCC-079	Use of Dynamic Cell Imaging™ (DCI) with the Van Gogh Platform in EUS-guided Sampling of Pancreatic Solid Lesions: A Feasibility Pilot Study	Maria Terrin
711	PPCC-080	A preliminary analysis of the diagnostic performance of a radiological artificial intelligence (AI) tool for the incidental detection of pancreatic lesions on computed tomography	Antonella Campisi
712	PPCC-081	Characteristics of pancreatic ductal adenocarcinoma following acute pancreatitis: a multicentric cohort analysis on 1006 cases	Ruggero Ponz De Leon Pisani

714	PPCC-082	Use of aspirin, statins, metformin and ace-inhibitors does not affect disease-free, disease-specific and overall survival in patients affected by pancreatic ductal adenocarcinoma	Ruggero Ponz De Leon Pisani
715	PPCC-083	PrePANC-NT Trial: Prehabilitation in Patients with Pancreatic Cancer During Neoadjuvant Therapy; Exploring an Understudied Window	Ahmet Anil Sahar
717	PPCC-084	The Role of Pancreatic Tumor/Remnant Tissue Density Ratio in Predicting Grade B and C POPF	Ulas Utku Sekerci
718	PPCC-085	Perivascular regions show reduced response to neoadjuvant chemotherapy in PDAC with vascular involvement	David Zschäpitz
719	PPCC-086	Patterns of recurrence in ampullary carcinoma - A Cross-Validation Study of the German Cancer Registry and an International Multicenter Cohort	Julia Straesser
721	PPCC-087	Clinical significance of tumor markers CA 19-9, CA 242, CA 50 and CA 72-4 in the diagnosis and staging of pancreatic cancer	Uros Djindjic
724	PPCC-088	Macrophage inhibitory cytokine 1, syncollin, and thrombospondin-2 in the differential diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis	Michalina Wieczorek
730	PPCC-089	A rare case of a 7 cm distal pancreatic ductal adenocarcinoma with a central 3 cm osseous metaplasia, oligometastatic to the liver, still alive 9 years after multi-visceral resection, excision of liver metastasis and chemotherapy	Sorin Traian Barbu
734	PPCC-090	Endoscopic Ultrasound (EUS) Findings of Metastatic Lesions to the Pancreas: A Retrospective Single-Center Study	Nevin Oruç
735	PPCC-091	Indications and prognostic factors in metastatic pancreatic cancer referred for radical treatment - a systematic review and meta-analysis	Chiara Maria Scandinavini
736	PPCC-092	Efficacy of immunonutrition in hepatobiliary cancer patients - a systematic review and meta-analysis	Bettina Csilla Budai
342	PPED-001	Is the prevalence of the exacerbations of the chronic pancreatitis related to the infectious season?	Zofia Oracz
<b>Group - 20</b>		<b>Chairs: Christopher Wolfgang (New York, USA), Orcun Can (Istanbul, Turkiye)</b>	
163	POTH-006	A rare case of pancreatic mass mimicking malignancy	Emine Gökce
741	PPCC-093	Postoperative Pancreatic Fistula and Recurrence in Pancreatic Ductal Adenocarcinoma	Hüseyin Fahri Martlı
745	PPCC-094	Liver metastasis and surgery for pancreas adenocarcinoma	Ahmet Çoker
748	PPCC-095	Hemopatch and pancreatic fistula	Ahmet Çoker
752	PPCC-096	High Early Recurrence Burden in Young Patients with Pancreatic Cancer Following Surgical Resection	Hüseyin Fahri Martlı
757	PPCC-097	Diagnostic Laparoscopy in Staging Exocrine Pancreatic Cancer: An Updated Review and Recommendations	Emilija Nikolovska Trpchevska
761	PPCC-098	Development and validation of a machine learning model predicting overall survival after resection of adenocarcinoma arising from intraductal papillary mucinous neoplasms (A-IPMN)	Christos Athanasiou
762	PPCC-099	Resection Margin Sites and Their Impact on Oncological Outcomes in Adenocarcinoma Arising from IPMN: Results from an International Multicenter Cohort Study	Vivek Peddakota

772	PPCC-100	The impact of neoadjuvant chemotherapy (nCT) on outcomes for patients with resectable pancreatic cancer	Ilya Vervekin
773	PPCC-101	Contemporary Adjuvant Chemotherapy for intraductal papillary mucinous neoplasms following pancreatic resection	Vivek Peddakota
774	PPCC-102	The "Acibadem sandwich protocol" - a novel neoadjuvant chemoradiotherapy approach in borderline resectable and locally advanced pancreatic cancer patients	Nur Ramođlu
785	PPCC-103	Primary Pancreatic Squamous Cell Carcinoma: A rare entity with unexpected EUS findings	David Miguel Ferro Tomás
799	PPCC-104	Comparison of Total Mesopancreatic Excision and Conventional Pancreaticoduodenectomy in the Surgical Treatment of Pancreatic Head Adenocarcinoma: Early Postoperative Outcomes	Cihan Ađalar
800	PPCC-105	Up-front Surgery for Anatomically Borderline Resectable and Locally Advanced Pancreatic Cancer (BR/LAPC): Contemporary Real-world Outcomes	Zipeng Lu
805	PPCC-106	Failure to Rescue After Pancreatoduodenectomy: A Single-Center Analysis Compared to GAPASURG Data	Congde Martin Xu
<b>Group - 28</b>		<b>Chairs: Okan Safak (Munich, Germany), Inesa Huivaniuk (Kyiv, Ukraine)</b>	
107	POTH-001	Highly effective but not lifelike? Prehabilitation in pancreatic surgery - Single-center experience	Matthias Glanemann
141	POTH-002	Small intestinal bacterial overgrowth (SIBO) and colonic dysbiosis in patients with combined fatty pancreas and metabolic dysfunction-associated steatotic liver disease (MASLD)	Nadiia Bieliaieva
144	POTH-003	The disease of Albrecht Dürer	Natalya Gubergrits
148	POTH-004	Microbiological Profile and Antimicrobial Resistance Patterns in Walled-Off Pancreatic Necrosis: A Single-Centre Retrospective Study	Tom Brand
158	POTH-005	Morphological patterns of inflammatory infiltration and fibrosis of the gastric mucosa in Helicobacter pylori-associated NSAID gastropathies in patients with ischemic heart disease	Almaza Madumarova
243	POTH-007	When Is Pancreatic Cancer Surveillance Efficient? A Microsimulation Study of Test Characteristics and Lifetime Risk	Oliver White
286	POTH-010	Pancreatic arteriovenous malformations as a manifestation of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease): a systematic review	Isabel De Jager
380	POTH-012	The Role of Helicobacter pylori in Pancreatic and Hepatic Steatosis	Mimoza Kankia
381	POTH-013	Surgical Anatomy of Peripancreatic Vessels in Pancreatic Resections	Spiros Delis
423	POTH-016	Bacterial Colonization in Resected Lymph Nodes During Pancreatic Surgery - A Pilot Study	Saadet Gurcinar
474	POTH-017	Impact of multimodal prehabilitation on postoperative outcomes after pancreatic resection: design of a prospective randomized controlled trial	Stefan Kolcun
530	POTH-018	PancreOS: A network of registries on Pancreatic Cancer	Raquel Benitez Dorta
572	POTH-019	Different intracellular pathways to calcium signal generation in pancreatic acinar cells activated by the cancer-promoting receptor for gastrin-releasing peptide (GRP) and by excitation of cholecystokinin (CCK) receptors	Muhanad E Salih

580	POTH-020	Diagnostic Performance of EUS versus MRCP for Choledocholithiasis: A Systematic Review	Taibe Haziri
652	POTH-021	Building quality improvement in HPB surgery in Ukraine: a nationwide needs assessment survey of surgeons and anesthesiologists	Inesa Huivaniuk
672	POTH-022	Trans-anastomotic Stent After Pancreatoduodenectomy: Impact on Early Postoperative Drain Fluid Amylase	Aya Maekawa
804	POTH-025	Fatty changes are more frequent in malignant pancreatic diseases	Mariia Kiriukova
<b>Group - 33</b>		<b>Chairs: Anna Caterina Milanetto (Padova, Italy), Roberto M. Montorsi (Amsterdam, The Netherlands)</b>	
206	PNET-001	Surgery or surveillance in sporadic Pancreatic Neuroendocrine Neoplasms in patients with age $\geq$ 75 years ?	Anna Caterina Milanetto
207	PNET-002	Duodenal Neuroendocrine Neoplasms. Surgical treatment and long-term results	Anna Caterina Milanetto
313	PNET-003	Pancreatic neuroendocrine tumor with bile duct stenosis: possible origin of the bile duct epithelium	Atsuko Kasajima
377	PNET-004	Pancreatic Neuroendocrine Neoplasms: Surgical Results from the Hellenic Pancreatic Neuroendocrine Tumor (HELPNET) Study Group	Spiros Delis
388	PNET-005	Laparoscopic Resection of Pancreatic Insulinoma in a Patient with Multiple Endocrine Neoplasia Type 1: A Case Report and Literature Review	Hao Luo
434	PNET-006	Pancreatic and ampullary neuroendocrine tumors: diagnosis, staging and management at a Moroccan tertiary center	Jaouhara Lahsini
458	PNET-007	Aurora kinase inhibition as a targeted therapy for ARID1A-deficient gastroenteropancreatic neuroendocrine carcinoma	Maria Pacalajova
598	PNET-008	Complex course of incidental pancreatic neuroendocrine tumor and inflammatory bowel disease with repeated surgical complications: a case report	Dóra Demeter
644	PNET-009	Two Cases of PP-producing PanNET with Atypical Histopathology and Invasive Character	Yoshihiro Hamada
698	PNET-010	Validation of Progression-Free Survival and Other Candidate Surrogate Endpoints for Overall Survival in Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis	Yuxin Wang

**Moda Poster Hall / 13.00 - 14.00**

\*Please kindly note that each presentation is allocated 4 minutes (3-minute presentation + 1-minute discussion)

<b>AbsRef</b>	<b>Pub Number</b>	<b>Title</b>	<b>Presenter</b>
<b>Group - 24</b>		<b>Chairs: Rup Talukdar (Hyderabad, India), Kazushige Uchida (Kochi, Japan)</b>	
586	PAPC-047	Interim results of the international LIFESPAN case-control study: lifestyle risk factors in acute pancreatitis	Dalma Dobszai
601	PAPC-048	Physiotherapy improves the functional status and physical strength of patients hospitalized with acute pancreatitis	Bence Tibor Soós
612	PAPC-049	Development and International Validation of a Deep Learning Model for Acute Pancreatitis Severity	Brigitta Teutsch
617	PAPC-050	Microbiological profile and temporal shifts in infected pancreatic necrosis in acute pancreatitis: A single-center descriptive study	Rodrigo Montoto Mejjide

635	PAPC-051	A randomized, placebo-controlled phase 3 study of plozasiran in patients with familial chylomicronemia syndrome: PALISADE - 1 year open-label extension	Maciej Banach
637	PAPC-052	Plozasiran decreases the risk of acute pancreatitis and may improve quality of life in Familial Chylomicronemia Syndrome	Maciej Banach
638	PAPC-053	Lipase Over Amylase in Acute Pancreatitis: A 1,293-Case Retrospective	Paula Filipa Rebelo
640	PAPC-054	When Lipase Fails: Predictors of False-Negative Acute Pancreatitis	Paula Filipa Rebelo
643	PAPC-055	Economic Impact of a Lipase-Only Diagnostic Strategy in Acute Pancreatitis: A Cost Modelling Analysis	Paula Filipa Rebelo
650	PAPC-056	Advances in the prediction of acute pancreatitis severity using machine learning models	Ying Lu Huang
674	PAPC-057	Incidence and severity of pancreatic exocrine insufficiency in acute pancreatitis during hospitalization: a prospective observational study	Jingwen Rao
675	PAPC-058	Transgastric endoscopic necrosectomy alone for pancreatic necrosis extending to the paracolic gutter in necrotizing pancreatitis: a retrospective cohort study	Jingwen Rao
691	PAPC-059	Local complications as the only criterion to define moderately severe acute pancreatitis	Juan Lin
692	PAPC-060	Pancreas Divisum: Experience of a Tunisian Center	Amal Khsiba
694	PAPC-061	Low-enzyme acute pancreatitis and the limitations of current diagnostic guidelines	Gefu Cai
98	PISL-001	Determinants of Islet Yield and Long-Term Metabolic Outcomes After Total Pancreatectomy With Islet Autotransplantation	Javed Latif
99	PISL-002	Comparative Outcomes of Total Pancreatectomy with Islet Autotransplantation in Hereditary Versus Non-Hereditary Chronic Pancreatitis: A 30-Year Single-Centre Study	Javed Latif
<b>Group - 25</b>		<b>Chairs: Yasar Colak (Istanbul, Türkiye), Lucía Guilabert Sanz (Elche, Spain)</b>	
720	PAPC-062	UICENS Strategy for Treating Infected Pancreatic Necrosis: A 10-Year Single-Center Experience from China	Hao Luo
727	PAPC-063	Inflammatory and hematological markers and clinical outcomes in hypertriglyceridemia-related acute pancreatitis: a nationwide multicenter cohort study	Yavuz Özden
728	PAPC-064	When Drugs Attack the Pancreas: Unmasking a Hidden Cause of Acute Pancreatitis	Ekram Hassan Hasanin
732	PAPC-065	Clinical Characteristics, Timing, and Outcomes of Atypical Hemolytic Uremic Syndrome in Acute Pancreatitis: An Individual Patient-Level Analysis	Boglárka Barna
737	PAPC-066	Red Cell Distribution Width at 24 Hours as an Early Predictor of Mortality and Severity in Acute Pancreatitis: A Multicenter Retrospective Cohort Study	Mihai Radu Pahomeanu
739	PAPC-067	Prognostic Value of Red Cell Distribution Width to Platelet Ratio in Acute Pancreatitis - A Multicenter Registry-Based Cohort Study	Mihai Radu Pahomeanu
740	PAPC-068	Day 1 Nucleated Red Blood Cell Count as a Prognostic Biomarker in Acute Pancreatitis: a Preliminary Result of a Multicenter Retrospective Cohort Study	Mihai Radu Pahomeanu
744	PAPC-069	Endosonographic differentiation of acute necrotizing pancreatitis and tumor-induced pancreatitis in the acute phase	Elena Mateska
749	PAPC-070	Nutritional status at admission and clinical outcomes in acute pancreatitis: a prospective observational cohort study	Olga Julia Zahariev
753	PAPC-071	Role of Lanreotide in the Management of Complex Pancreatic Fluid Collections: A Retrospective Review	Mudassar Ghazanfar
759	PAPC-072	Male sex is associated with worse outcomes in acute pancreatitis: post-hoc analysis of the WATERLAND randomized trial	Lucía Guilabert

777	PAPC-073	Machine Learning-Based Risk Stratification in Acute Pancreatitis: Development of a Balanced Random Forest Model for Predicting Severity of Pancreatitis and Critical Care Admission	Christos Athanasiou
778	PAPC-074	Depression, Anxiety, and Outcomes in Acute Pancreatitis: A Prospective Observational Study	Tibor Dániel Fehér
796	PAPC-075	Effect of methionine containing antioxidant cocktail on recurrence of acute pancreatitis in children	Pullara Kashif Suleman
100	PISL-003	Portal venography and portal venous pressure assessment following total pancreatectomy and islet autotransplantation using a recanalised umbilical vein catheter	Javed Latif
161	PISL-004	A 30-Year Multidisciplinary Framework for Assessment and Consent in Total Pancreatectomy with Islet Autotransplantation	Javed Latif
769	PISL-007	Islet autotransplantation in pancreatic trauma: evaluating feasibility, safety, and metabolic outcomes after pancreatic resection	Sanjay Pandanaboyana
<b>Group - 26</b>		<b>Chairs: Asif Halimi (Stockholm, Sweden), Giovanni Marchegiani (Padova, Italy)</b>	
102	PCYS-001	Obesity as a Risk and Prognostic Factor for Disease Progression in Intraductal Papillary Mucinous Neoplasm (IPMN): A Systematic Review and Meta-analysis	Charlotte Gustorff
152	PCYS-003	Assessing surveillance for branch duct IPMN: Number needed to screen and standardized incidence ratio analysis	Julia Moghadampour
237	PCYS-004	Treatment of Pancreatic Pseudocysts Under Endosonographic Guidance	Igor Khomiak
263	PCYS-005	Pancreatic acinar cell cystadenoma: single-center experiences and a systematic review	Miroslav Vujasinovic
346	PCYS-007	Risk factors associated with high-grade dysplasia and adenocarcinoma in mucinous cystic neoplasm of the pancreas	Alejandro Gutierrez Castillo
610	PSUR-048	Unraveling the protective effect of female sex on outcome after pancreatoduodenectomy: less complications or smaller impact? for the Dutch Pancreatic Cancer Group	Greta Donisi
621	PSUR-049	Comparison of surgery outcomes for pancreatic ductal adenocarcinoma according to tumour location: eleven years of experience in a tertiary hospital	Núria Llorach Perucho
622	PSUR-050	Comparison of pancreaticoduodenectomy with and without mesenteric-portal venous resection in pancreatic ductal adenocarcinoma: 11 years of experience in a tertiary institution	Francisco Garcia Borobia
626	PSUR-051	Standardising Extravasation Injury Management: A Retrospective Audit & Future Improvements	Berin Gorgun
636	PSUR-052	The impact of inflammation and biliary microbiology on postoperative morbidity after cholecystectomy - a single-center retrospective cohort study	Patrick Hofmockel
646	PSUR-053	Perioperative transfusions of blood products and the effect on postoperative morbidity and mortality in pancreatic head resections- A unicenter, retrospective analysis	Isabel Kraemer
659	PSUR-054	The burden of vascular resection in pancreatic surgery: myth or reality	Vanessa Cusano
667	PSUR-055	Preoperative GNRI fails to predict clinically relevant postoperative pancreatic fistula after pancreatoduodenectomy and distal pancreatectomy for PDAC: an external validation study	Miguel Fróis Borges
668	PSUR-056	Artificial intelligence-derived inflammatory and nutritional profiles identify high-risk patients undergoing pancreatic cancer resection	Miguel Fróis Borges
<b>Group - 27</b>		<b>Chairs: Johanna Laukkarinen (Tampere, Finland), Andrea Sheel (Lancashire, UK)</b>	
639	PCYS-011	Scoping review of cost-effectiveness of surveillance of intraductal papillary mucinous neoplasms	Dana Sochorova
670	PCYS-012	ATHENA: A Multimodel AI Decision-Support Tool for Multidisciplinary Evaluation of Pancreatic Cysts	Claudio Ricci

747	PCYS-013	MACHINE-LEARNING-POWERED ENDOSCOPIC ULTRASOUND DETECTS MORPHOLOGICAL FEATURES FOR PREDICTING MALIGNANCY IN IPMNs: RESULTS FROM THE "IMAGE" STUDY FROM A TERTIARY REFERRAL CENTER	Matteo Tacelli
750	PCYS-014	Can we predict biopsy accuracy in IPMNs? Preoperative prediction of cytology-histology concordance combining EUS-FNA and a machine learning approach	Matteo Tacelli
802	PCYS-015	Single-center experience with endoscopic management of demarcated walled-off pancreatic necrosis (WOPN)	Dominik Horváth
669	PSUR-057	Frailty predicts postoperative mortality in pancreatic resection for cancer	Miguel Fróis Borges
681	PSUR-058	Intraoperative Indocyanine Green Angiography to Prevent Functional Deficit after Tail-Preserving Pancreatectomy - An Experience of a Tertiary Care Centre of Nepal	Prabir Maharjan
682	PSUR-059	CRP kinetics and NLR as early predictors of clinically relevant POPF following pancreatic surgery	Mario Gruppo
704	PSUR-060	Toward mechanically realistic pancreatic surgery simulation: multi-modal characterization of relevant tissues	Arianna Callera
707	PSUR-061	Concomitant Major Complication (CMC) score defines postoperative trajectories and outcomes after Pancreatoduodenectomy	Alice Cattelani
725	PSUR-062	Simultaneous or staged liver resection in the treatment of synchronous colorectal cancer metastases	Predrag Zdujic
731	PSUR-063	Pancreatic metastases: retrospective case series from a tertiary referral center	Konstantinos Iliakopoulos
767	PSUR-064	Comparison of different types of pancreatic anastomoses after pancreaticoduodenectomy (modified Blumgart anastomosis vs invagination pancreaticojejunostomy)	Ilya Vervekin
794	PSUR-065	Double roux reconstruction to reduce pancreatobiliary reflux and its potential role in preventing malignancy after pancreatoduodenectomy	Eylül Kösele
<b>Group - 31</b>		<b>Chairs: Jayanta Samanta (Chandigarh, India), Miroslav Vujasinovic (Stockholm, Sweden)</b>	
526	PCYS-008	Elevated CA19-9 is a good predictor of adverse long-term outcomes after pancreatic resection for adenocarcinoma arising from IPMN. Results from an international multicenter cohort study	Vivek Peddakota
536	PCYS-009	Rethinking the Role of Acute Pancreatitis in Intraductal Papillary Mucinous Neoplasms: A Multicenter Evaluation of Radiologic, Clinical, and Biological Predictors of Neoplastic Progression	Riccardo Pellegrini
238	PCYS-010	Risk Stratification of Malignancy in Pancreatic Intraductal Papillary Mucinous Neoplasm Using 2024 Kyoto Guidelines: Impact of Worrisome Features	Jisun Lee
614	PEND-032	EUS-Guided gastroenterostomy versus enteral stenting for malignant gastric outlet obstruction in pancreatic cancer: A real-world comparative study	Sofía Barral Diaz
615	PEND-033	Choosing the Optimal EUS-Guided Drainage in Malignant Distal Biliary Obstruction: Choledochoduodenostomy vs gallbladder drainage	José Lariño Noia
673	PEND-034	From Pixels to Decision-Making: Utilizing Multi-scale Attention and Self-supervised Baseline Models to Achieve Pathologist Cognitive Workflow in Pancreatic ROSE	Jie Hao
696	PEND-035	Microbial Profile of Bile Cultures in Patients with Cholangitis Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP): A Systematic Review and Meta-Analysis	Yoon Kee Beck
701	PEND-036	EUS-guided HepaticoGastrostomy in pancreatobiliary malignancies: prospective assessment of efficacy and safety according to indication and anatomy	Roberto Junior Ruggiero
766	PEND-038	Clinical outcomes of EUS-guided multiple transluminal gateway drainage for walled-off pancreatic necrosis and pseudocysts: a single-center experience	Patryk Kaczor
781	PEND-039	Thirty-day hospital admission following Outpatient ERCP: Safety Profile and Predictive Factors	David Miguel Ferro Tomás

787	PEND-040	Safety and efficacy of precut techniques for biliary cannulation in Outpatient ERCP	David Miguel Ferro Tomás
577	PIMG-003	Comparative assessment of pancreatic stiffness in fatty pancreas vs. healthy controls using ultrasound elastography	Emilija Nikolovska Trpchevska
716	PIMG-005	Radiomics and Artificial Intelligence in Pancreatic Endoscopic Ultrasound: Can We Detect Cancer Before It Becomes Visible?	Irina Florina Cherciu Harbiyeli
<b>Group - 32</b>		<b>Chairs: Stephen Pandol (Los Angeles, USA), Daniel de la Iglesia Garcia (Madrid, Spain)</b>	
182	PEDI-001	Clinical significance and accuracy of continuous glucose monitoring in pancreatectomy patients	Yoo Jin Choi
250	PEDI-002	Real-world evaluation of suspected pancreatic exocrine insufficiency and generation of a reasonable workup - a cohort study from a large pancreatic disease center in Germany	Jakob Vielhauer
142	PEPI-002	Exocrine pancreatic insufficiency or lactase deficiency: differential diagnosis	Nadiia Bieliaieva
150	PEPI-004	Long-term Nutritional Outcomes After Distal Pancreatectomy for Benign Pancreatic Cysts: Impact of Pancreatic Enzyme Replacement Therapy	Yoonchan Lee
205	PEPI-006	Pancreatic exocrine insufficiency after esophageal and gastric surgery: the PEGAS study	Miroslav Vujasinovic
281	PEPI-007	Comparative renal effectiveness of newer glucose-lowering drugs with metformin in new-onset diabetes after pancreatitis patients: a target trial emulation cohort study	Di Wu
307	PEPI-008	Features of exocrine insufficiency in long-term follow-up after proximal pancreatic resection	Yulia Osipenko
318	PEPI-009	Symptoms of Pancreatic Exocrine Insufficiency Correlate with Stool Consistency Rather Than EUS Findings	Joowon Chung
371	PEPI-010	Diagnostic Performance and Cost Implications of Fecal Elastase in Evaluating Steatorrhea and Exocrine Pancreatic Dysfunction	Motaz Ashkar
421	PEPI-011	Low bone mineral density and fracture risk in chronic pancreatitis: The impact of pancreatic exocrine insufficiency	Andreia Rei
583	PEPI-013	Familial fatty pancreas due to transheterozygous mutations in MECOM and CELA3B	Maren Ewers
611	PEPI-014	Risk factors for pancreatic exocrine insufficiency after acute pancreatitis: a systematic review and meta-analysis	Orsolya Eperjesi
791	PEPI-017	Pancreatic Exocrine Insufficiency as a Marker of Disease Progression in IPMN Surveillance: IPEX Study	Giacomo Deiro

**Beşiktaş Poster Hall / 13.00 - 14.00**

\*Please kindly note that each presentation is allocated 4 minutes (3-minute presentation + 1-minute discussion)

<b>AbsRef</b>	<b>Pub Number</b>	<b>Title</b>	<b>Presenter</b>
<b>Group - 21</b>		<b>Chairs: Andrea Geisz-Fremy (Boston, USA), Maria Ines Vaccaro (Buenos Aires, Argentina)</b>	
482	PPCE-049	Interim outputs of the United Kingdom Early Detection Initiative for pancreatic cancer	Lucy Oldfield
484	PPCE-050	Deciphering the Genomic Drivers of Neural Invasion in Pancreatic Cancer	Basak Kavaklioglu
488	PPCE-051	A circulating protein signature of pancreatogenic disease detectable up to five years before pancreatic cancer diagnosis	Irena Stefanova
489	PPCE-052	An advanced preclinical model for testing combination therapy in pancreatic cancer using a dynamic culture platform	Verona Buocikova
494	PPCE-053	ROR1 Expression in Lymph Nodes, Tumor Tissue, and Immune Cells as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma	Anke Mittelstädt

498	PPCE-054	Deep learning-driven identification of peripherally restricted NPY1R antagonists to disrupt nerve-tumor crosstalk in pancreatic ductal adenocarcinoma	Esra Nalbat
510	PPCE-055	Integrative molecular analysis of pancreatic cancer precursor lesions: predictive models for biological aggressiveness and tumor development	Raka Aziz
531	PPCE-057	Decitabine reshapes the transcriptional response to gemcitabine in orthotopic MIAPaCa-2 pancreatic cancer xenografts	Bozena Smolkova
533	PPCE-058	Targeting VMP1 to Overcome Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma	Maria Ines Vaccaro
551	PPCE-060	GLOPH3-ERK1/2-E2F1 positive feedback loops promote pancreatic cancer progression	Wang Zheng
552	PPCE-061	The Fas receptor promotes neural invasion by inducing a shift from apoptotic to migratory signaling in pancreatic cancer	Clara M. Müller
553	PPCE-062	Integrated Single-Cell Analysis Identifies CD55 as a Mediator of Neoadjuvant Chemotherapy Resistance in PDAC	Zongyao Chen
575	PPCE-063	Schwann Cell derived Chromosome 4 Chemokines modulate Cancer Cell Viability	Mara R Goetz
576	PPCE-064	Knock-out of mitophagy receptors Bnip3 and Nix results in increased therapy response of murine pancreatic cancer cells	Simon Knoll
587	PPCE-065	Immunomodulatory impact of PTPN11/SHP2-based vertical RAS-MAPK pathway inhibition in pancreatic cancer	Asma Alrawashdeh
<b>Group - 22</b>		<b>Chairs: Heiko Witt (Munich, Germany), Didem Karakas Zeybek (Istanbul, Turkiye)</b>	
590	PPCE-066	Genome-wide CRISPR/cas9 screening for oxaliplatin resistance in pancreatic cancer	Jung Won Chun
603	PPCE-067	Micro-CT analysis can distinguish features of PDAC: preliminary experience	Kaisa Tyrväinen
604	PPCE-068	Multi-trait genome-wide association analysis identifies novel susceptibility loci for pancreatic cancer	Yongping Chen
609	PPCE-069	Multinucleated giant cells in human pancreatic cancer are a distinct macrophage population undergoing a DNA damage response and associated to an aggressive tumor microenvironment	Greta Donisi
623	PPCE-070	The CTRB2del Variant Confers Increased Risk of Pancreatic Ductal Adenocarcinoma in the Hungarian Population	Sarah Ammar Khodja
628	PPCE-071	Combating Chemoresistance in Pancreatic Cancer: Insights from Transcriptomics and dCK-Independent Therapy	Giulia Lencioni
629	PPCE-072	The roles of Galnt2 and St3gal6 genes on neural invasion in pancreatic cancer	Alper Dogruoz
634	PPCE-073	Integrative CUT&RUN and RNA-seq Analyses Reveal STAT3-Dependent Regulatory Networks in IL-17-Stimulated Pancreatic Acinar Cells	Mahnoosh Ostadreza
641	PPCE-074	Exosome-driven schwann cell-cancer cell communication promotes pancreatic cancer aggressiveness	Didem Karakas
647	PPCE-075	The impact of RNF43 mutation on the tumor-stroma crosstalk during earlier pancreatic carcinogenesis	Matthäus Felsenstein
648	PPCE-076	The mechanism of macrophage-induced PDAC cell senescence driven by ENO1-mediated histone lactation driving pancreatic cancer stemness	Luying Huang
664	PPCE-077	Early neural remodeling initiates at the Acinar-to-Ductal Metaplasia stage in pancreatic carcinogenesis	Alper Dogruoz
697	PPCE-079	Background. Pancreatic ductal adenocarcinoma (PDAC) is characterized by an aggressive clinical course and profound immunotherapy resistance, driven largely by an immunosuppressive tumor microenvironment (TME) dominated by tumor-associated macrophages	Svetlana M. Gramatiuk
700	PPCE-080	Significance of lncRNAs in diagnosis and prognosis of pancreatic cancer	Nevin Oruc

703	PPCE-081	Which sugar is sweeter for pancreatic cancer?	Nevin Oruc
<b>Group - 23</b>		<b>Chairs: Ivonne Regel (Halle, Germany), Nevin Oruc (Izmir, Turkiye)</b>	
297	PGEN-002	Germline genetic variants associated with chemotherapy response and survival in non-metastatic pancreatic ductal adenocarcinoma	Manuel Gentiluomo
461	PGEN-003	Rare variant analysis suggests ASIC2 and KCNJ2 as candidate genes for pancreatic cancer risk in the UK Biobank cohort study	Emma Barreto
602	PGEN-005	Dissecting pancreatic ductal adenocarcinoma genetic architecture through fine-mapping of susceptibility loci	Cosmeri Rizzato
630	PGEN-007	Refining Pancreatic Cancer Surveillance Through Context-Aware Germline Variant Interpretation	William Greenhalf
662	PGEN-009	NR5A2-CTRB2 genetic interaction increases PDAC risk by impairing pancreatic stress responses	Sarah Klaus
746	PGEN-010	Clinical Relevance of Germline CHEK2 and CDKN2A Variants in Pancreatitis and Pancreatic Cancer	Stanislaw Zbigniew Gluszek
793	PGEN-012	The role of extrachromosomal DNAs (ecDNAs) in chemocytotoxic resistance in pancreatic cancer	Sadaf Shabbir Mughal
722	PPCE-082	The lncRNA within small extracellular vesicles promotes the neuron-cancer crosstalk in pancreatic cancer	Linhan Ye
723	PPCE-083	Single-cell profiling identifies MMP1-high inflammatory CAFs associated with neoadjuvant chemotherapy resistance in pancreatic ductal adenocarcinoma	Yihong Cai
733	PPCE-084	Neuropeptide Y Promotes Tumor-Nerve Crosstalk and Neural Invasion in Pancreatic Ductal Adenocarcinoma	Shenghan Wang
756	PPCE-085	Visualizing pancreatic neural structures using Golgi-Cox staining method	Alper Dogruoz
764	PPCE-086	Mechanisms for stroma-induced secondary chemoresistance in pancreatic adenocarcinoma	Corinne Bousquet
771	PPCE-087	LAMA3 and LAMA4 are upregulated and prognostically significant in pancreatic cancer	Nevin Oruc
775	PPCE-088	NOL4 is a tumor suppressor gene that plays critical role in chronic pancreatitis related oncogenesis	Nevin Oruc
792	PPCE-089	Tumor-Educated Platelets Acquire PDAC-Associated RNA: A Multicohort Diagnostic Signature with in vitro Confirmation	Aldo Pastore
798	PPCE-090	Deep learning-enabled multiomics reveals neural drivers of perineural invasion in PDAC	Raphael Kfuri Rubens
<b>Group - 29</b>		<b>Chairs: Ujjwal Mahajan (Munich, Germany), Yetiş Gültekin (Cambridge, USA)</b>	
208	PAPE-001	Mitigating organ failure with a novel oral anti-lipase treatment targeting gut lymph in experimental severe acute pancreatitis	John Windsor
227	PAPE-002	Proteomic Profiling Reveals Distinct Sex-Specific Molecular Mechanisms and Inflammatory Pathways in Severe Acute Pancreatitis	Aditi Bhargava
233	PAPE-003	Effects of GLP-1 Receptor Agonists on Secretagogue-induced Acute Pancreatitis in Mice	Rebecca Reardon Lochbaum
270	PAPE-004	Extracellular vesicle-mediated inflammation in acute pancreatitis is attenuated by Lactated Ringer's solution: involvement of protein lactylation	Olga Armengol Badia
277	PAPE-005	Pancreatic tissue remodeling in experimental pancreatitis is regulated by activation and recruitment of systemic immune cells via the CXCR3 chemokine system	Juliane Glaubitz
325	PAPE-006	Differential regulation of pancreatic duct HCO <sub>3</sub> <sup>-</sup> secretion by inflammatory cytokines	Mingjuan Li
328	PAPE-007	Role of the ER-cargo protein CLN8 in the pathophysiology of acute pancreatitis	Lukas Zierke
379	PAPE-008	The inhibition of matrix-metalloproteases restricts the immune cell infiltration and ameliorates the disease severity in acute pancreatitis	Shenja Buchholz

401	PAPE-010	GLP-1 receptor agonists induce non-inflammatory pancreatic hypertrophy and ameliorate acute pancreatitis in mice	Zhengyang Fan
414	PAPE-011	Interleukin-1 family cytokines regulate pancreatic fibroblast activation and immune cell recruitment in experimental acute pancreatitis	Ben Lewin Becker
451	PAPE-012	Expression and Functional Role of H <sub>2</sub> S-Producing Enzymes in Pancreatic Acinar Cell Injury	Erik Orján
456	PAPE-013	Mitigating ferroptosis-induced cellular damage in mouse pancreatic acinar cells	Bálint Sándor
483	PAPE-014	Hepatic metabolite N-acetylaspartic acid alleviates acute pancreatitis by restoring mitophagy via BCL2L13	Shiyu Liu
516	PAPE-015	Body Mass Index and Psychological Alterations in Patients with Acute Pancreatitis	Zsofia Nemeth
676	PAPE-016	Therapeutic Inhibition of Pancreatic Triglyceride Lipase Ameliorates Hypertriglyceridemic Pancreatitis in mice	Jingwen Rao
742	PAPE-017	The pancreatic phenotype of Cfr <sup>Δpanc</sup> mice is driven by the ductal compartment	Henrik Einwächter
<b>Group - 30</b>			
<b>Chairs: Raghu Kalluri (Houston, USA), Matthias Sandler (Mecklenburg-Vorpommern, Germany)</b>			
160	PCPE-001	Therapeutic targeting of secreted osteopontin attenuates fibrogenesis in experimental chronic pancreatitis	Emine Gökce
175	PCPE-002	Immune-related gene signatures and immune cell infiltration in chronic pancreatitis: an integrated bioinformatics analysis	Xiaobo Wang
248	PCPE-003	Plasminogen activator inhibitor-1 as a Potential Antifibrotic Target in Chronic Pancreatitis	Tünde Molnár
276	PCPE-004	Cholesterol-Mediated communications between acinar cells and β cells in chronic pancreatitis	Yitian Zhou
293	PCPE-005	Aptamer-aided anti-inflammatory programming of resident tissue macrophages for recuperation of chronic pancreatitis	Jianying Xu
301	PCPE-006	Decoding Mesenchymal Control of Chronic Pancreatitis via Prrx1 <sup>+</sup> Lineage Tracing and Single-Cell Profiling	Ruoxuan Dai
339	PCPE-007	The management of pancreaticopleural fistulas: a single centre case series	Madhav Sanatkumar Dave
375	PCPE-008	Investigating changes in endocrine function in a mouse model of chronic pancreatitis	Gergely Koszta
455	PCPE-009	Restoring ductal CFTR function as a disease-modifying strategy in chronic pancreatitis	Tamara Madácsy
466	PCPE-010	Impact of TRPA1 on Acute Injury and Fibrotic Remodeling in Pancreatitis	Ola Salamah
471	PCPE-011	A high-fat diet is insufficient to drive pancreatic intraepithelial neoplasia from acinar-to-ductal metaplasia	Cecile Haumaitre
486	PCPE-012	IL-4/IL-13/STAT6 signalling regulates fibrogenesis and organ regeneration via suppression of the IL-6/STAT3 pathway during chronic pancreatitis	Matthias Sandler
490	PCPE-013	Production of Anti-CX3CR1 Monoclonal Antibody for Use in the Preclinical Treatment of Chronic and Acute Pancreatitis	Tayyar Emir Gözeler
538	PCPE-014	Pancreatitis leaves an epigenetic imprint on acinar cells that shapes regeneration and plasticity	Yiming Zhang
658	PCPE-015	A CX3CL1-CX3CR1-Driven Neuro-Immune Circuit Amplifies Pain in Pancreatitis and Offers a Druggable Therapeutic Entry Point	Ibrahim Halil Gürcinar
751	PCPE-016	APOBEC3A is a molecular link between chronic inflammation and immune activation, driving a feed-forward loop that exacerbates pancreatic injury and promotes mutagenesis	Intisar Salim
782	PCPE-017	Re-evaluating the role of TRPV6 deficiency in human and mouse pancreatitis	Mate Sandor